The company anticipates that this approval will expand to children ages 5 to 11 for the upcoming respiratory virus season, according to the email that the CDC’s National Center for Immunization and Respiratory Diseases sent to state and local health officials on Friday. But vaccine access for the youngest children, who are most vulnerable to severe illness from a Covid-19 infection, would be significantly more limited if the FDA does not renew emergency authorization for the Pfizer vaccine for children under 5. “We are currently in discussions with the agency on potential paths forward and have requested that the EUA for this age group remain in place for the 2025-2026 season,” Pfizer said in a statement.
Author: Meg Tirrell
Published at: 2025-08-12 22:32:40
Still want to read the full version? Full article
